Peptide Sciences Voluntary Shutdown (March 2026)

On March 6, 2026, Peptide Sciences — one of the largest and most well-known grey-market peptide vendors in the United States — voluntarily ceased operations without public explanation.

Background

Peptide Sciences had operated as a “research chemical” vendor, selling peptides labeled “for research purposes only” to avoid FDA regulation of unapproved drugs. Despite this labeling, the vast majority of their customer base consisted of individuals using the peptides for personal therapeutic purposes.

Scale of Operations

• Estimated revenue: $7M+ per month at peak
• Product catalog: 100+ peptide products including BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHRP-2, GHRP-6, Melanotan II, Selank, Semax, and GHK-Cu
• Reputation: Widely regarded as one of the more reputable grey-market vendors, with third-party testing certificates of analysis (COAs) published for most products
• Customer base: Estimated tens of thousands of active customers

The Shutdown

The closure was abrupt:

• Website was taken offline without advance warning
• No press release or public statement was issued
• Customer orders in transit were reportedly fulfilled
• No indication of asset seizure or criminal charges
• The term “voluntary closure” suggests a proactive decision rather than a forced shutdown

Possible Explanations

While no official reason was given, several factors likely contributed:

1. Regulatory pressure: The FDA had been increasing enforcement actions against peptide vendors throughout 2025-2026
2. Kennedy reclassification: The February 2026 announcement signaled that legal compounding access might return, potentially reducing grey-market demand
3. Legal risk calculus: At $7M+/month revenue, the operation was large enough to attract serious federal attention
4. Industry trend: Science.bio had already shut down in January 2026, suggesting coordinated or cascading industry exits
5. Potential behind-the-scenes enforcement: FDA warning letters or DOJ inquiries may have been issued privately before public action

Market Impact

The shutdown of Peptide Sciences created significant disruption:

• Supply gap: Customers lost access to a trusted vendor, pushing them toward less vetted sources
• Price increases: Remaining vendors raised prices as demand concentrated
• Quality concerns: With fewer established vendors, counterfeit and underdosed products became more common
• Community reaction: Peptide forums and subreddits saw intense discussion and panic buying from remaining vendors

Broader Context

The Peptide Sciences shutdown was part of a larger pattern of grey-market vendor closures in early 2026:

• Science-Bio-Shutdown-January-2026 — January 2026
• Peptide Sciences — March 2026
• Several smaller vendors also closed or reduced product offerings

This wave of closures occurred in the gap between the original Category 2 restrictions and the pending Kennedy reclassification, creating a period of maximum uncertainty for the peptide market.

Related Notes

• Science-Bio-Shutdown-January-2026 — earlier vendor closure
• FDA-Category-2-Designations-2023-2024 — regulatory backdrop
• FDA-Warning-Letters-April-2026 — continued FDA enforcement
• FDA-Reclassification-Announcement-Feb-2026 — pending regulatory reversal